Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Predicting Outcomes in Pediatric Ulcerative Colitis for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program

Autor: Meyer EO, Aardoom M, Ricciuto A, Navon D, Carman N, Aloi M, Bronsky J, Däbritz J, Dubinsky M, Hussey S, Lewindon P, Martín-de-Carpi J, Navas-López VM, Orsi M, Ruemmele FM, Russell RK, Veres G, Walters TD, Wilson DC, Kaiser T, de Ridder L, Griffiths A, Turner D

Publikováno v: Gastroenterology
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname

BACKGROUND & AIMS: A better understanding of prognostic factors in ulcerative colitis (UC) could improve patient management and reduce complications. We aimed to identify evidence-based predictors for outcomes in pediatric UC, which may be used to op

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9041fabe78eb9c6efb65abae3dd6611e
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18192

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN

Autor: Paediatric IBD Porto Group of ESPGHAN, Joosse, M E, Aardoom, M A, Kemos, P, Turner, D, Wilson, D C, Koletzko, S, Martin-de-Carpi, J, Fagerberg, U L, Spray, C, Tzivinikos, C, Sladek, M, Shaoul, R, Roma-Giannikou, E, Bronsky, J, Serban, D E, Ruemmele, F M, Garnier-Lengline, H, Veres, G, Hojsak, I, Kolho, K L, Davies, I H, Aloi, M, Lionetti, P, Hussey, S, Veereman, G, Braegger, C P, Trindade, E, Wewer, A V, Hauer, A C, de Vries, A C H, Sigall Boneh, R, Sarbagili Shabat, C, Levine, A, de Ridder, L

Publikováno v: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Alimentary Pharmacology & Therapeutics, 48(5), 523-537. Wiley-Blackwell Publishing Ltd

Background: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-relate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a334ca65bb9a1aa30e5472a381e5ff57
https://doi.org/10.1111/apt.14893

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN

Autor: Joosse, M. E. Aardoom, M. A. Kemos, P. Turner, D. and Wilson, D. C. Koletzko, S. Martin-de-Carpi, J. Fagerberg, U. L. Spray, C. Tzivinikos, C. Sladek, M. Shaoul, R. and Roma-Giannikou, E. Bronsky, J. Serban, D. E. Ruemmele, F. M. and Garnier-Lengline, H. Veres, G. Hojsak, I. Kolho, K. L. and Davies, I. H. Aloi, M. Lionetti, P. Hussey, S. and Veereman, G. Braegger, C. P. Trindade, E. Wewer, A. V. and Hauer, A. C. de Vries, A. C. H. Boneh, R. Sigall Shabat, C. Sarbagili Levine, A. de Ridder, L. Paediat IBD Porto Grp ESPGHAN

Background: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-relate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::cfc3cf51bef8ead6c6d48706841ff661
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3181301

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.